Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster immunogenicity and safety study of MenACYW quadrivalent meningococcal conjugate vaccine
2018-001470-18Phase 3
- Sponsor
- Sanofi
- Start
- Jul 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Meningococcal ACWY conjugate vaccine in meningococcal disease (2 arms), sponsored by Sanofi. Primary endpoints: Seroresponse to meningococcal serogroups A, C, Y, and W and Non-inferiority of booster seroresponse versus licensed MCV4.
02
Drugs
Meningococcal ACWY conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2018-001470-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001470-18.